

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human B7-H4 in direct ELISAs.
Source	Recombinant Monoclonal Rabbit IgG Clone # 2318A
Purification	Protein A or G purified from cell culture supernatant
Immunogen	Mouse myeloma cell line, NS0-derived human B7-H4 Met1-Ser988 Accession # Q7Z7D3
Conjugate	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Flow Cytometry	0.25-1 µg/10 ⁶ cells	HEK293 Human Cell Line Transfected with Human B7-H4 and eGFP

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. <ul style="list-style-type: none"> 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

B7-H4, also known as VTCN1, B7x and B7S1, is a 50-80 kDa glycosylated member of the BTN/MOG family of immunomodulatory protein (1, 2). Mature human B7-H4 consists of a 235 amino acid (aa) extracellular domain (ECD) with one Ig-like V-set domain and one Ig-like C2-set domain, a 21 aa transmembrane segment, and a 2 aa cytoplasmic tail (3-5). Within the ECD, human B7-H4 shares 90% aa sequence identity with mouse and rat B7-H4. It shares 22%-28% aa sequence identity with human B7-1, B7-2, B7-H1, B7-H2, B7-H3, and PD-L2. Alternate splicing of human B7-H4 generates an additional isoform that lacks the first Ig-like domain. B7-H4 is expressed on the surface of activated lymphocytes, macrophages, monocytes, dendritic cells, epithelial cells, and bone marrow-derived mesenchymal stem cells (4-8). Following binding to activated T cells, B7-H4 serves as a co-inhibitor of the T cell response. This is accomplished by reverse signaling that can induce either cell cycle arrest, or apoptosis in B7-H4 expressing cells (3-5, 9, 10). B7-H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis (2, 7, 11, 12). A soluble form of B7-H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status (13-15). Soluble B7-H4 functions as a decoy molecule that blocks the inhibitory influence of B7-H4 on immune activation (15). Despite evidence for the involvement of B7-H4 in immune regulation, mice deficient in its expression do not show significant immune deficiencies, suggesting compensation by other molecules *in vivo* (16).

References:

- Yi, K.H. and L. Chen (2009) Immunol. Rev. **229**:145.
- Salceda, S. *et al.* (2005) Exp. Cell Res. **306**:128.
- Zang, X. *et al.* (2003) Proc. Natl. Acad. Sci. **100**:10388.
- Prasad, V.R. *et al.* (2003) Immunity **18**:863.
- Sica, G.L. *et al.* (2003) Immunity **18**:849.
- Kryczek, I. *et al.* (2006) J. Exp. Med. **203**:871.
- Tringler, B. *et al.* (2005) Clin. Cancer Res. **11**:1842.
- Xue, Q. *et al.* (2010) Stem Cells Dev. **19**:27.
- Song, H. *et al.* (2008) Cancer Lett. **266**:227.
- Park, G.B. *et al.* (2009) Immunology **128**:360.
- Zang, X. *et al.* (2007) Proc. Natl. Acad. Sci. **104**:19458.
- Krambeck, A.E. *et al.* (2006) Proc. Natl. Acad. Sci. **103**:10391.
- Simon, I. *et al.* (2006) Cancer Res. **66**:1570.
- Thompson, R.H. *et al.* (2008) Cancer Res. **68**:6054.
- Azuma, T. *et al.* (2009) PLoS Med. **6**:e1000166.
- Suh, W.-K. *et al.* (2006) Mol. Cell. Biol. **26**:6403.

Human B7-H4 Alexa Fluor® 594-conjugated Antibody

Recombinant Monoclonal Rabbit IgG Clone # 2318A

Catalog Number: FAB65764T

100 µg, 25 Tests

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.